Valeant won't pay whatever it takes for Allergan -CEO
April 22 (Reuters) - Valeant Pharmaceuticals Inc won't pay whatever it takes to acquire rival Allergan Inc , and it will not turn its bid into an all-cash deal, Valeant Chief Executive Michael Pearson said on Tuesday in New York.
Valeant and activist investor Bill Ackman made an unsolicited $47 billion bid to buy Botox maker Allergan as it seeks to become one of the world's five biggest drug companies. (Reporting by Bill Berkrot in New York; Writing by Rod Nickel in Winnipeg, Manitoba; Editing by Meredith Mazzilli)
© Thomson Reuters 2017 All rights reserved.